Oscar Saxelby-Lee gets ‘super cells’ after having stem cell transplant from dad to fight off cancer – Ledbury Reporter

A SIX-year-old boy has received his super cells after having a stem cell transplant to fight off cancer.

Oscar Saxelby-Lee received his transplant yesterday (March 13) from his dad, Jamie Lee, who donated his cells to his little boy.

The Hand in Hand for Oscar Facebook page announced the heart-warming news: May these super cells be the beginning of something special just like you Ozzy Bear. We hope this gift will allow you a brand-new start to good health and end the monstrous ordeals you have been faced with. You will always have us by your side, hoping, praying and fighting for the brighter future you so very much deserve.

The emotive post continued: Daddy will always be with you, both inside and out now. How amazing is that. And how utterly amazing are you. You are so so close baby, keep going. Now for the difficult part of growing them and keeping him stable, but hes got this."

Oscar experienced a few slight implications during the transplant due to a reaction, but his parents have assured he is safe and is doing well.

Oscar has been in Singapore with his parents, Olivia Saxelby and Mr Lee, receiving CAR-T therapy after the community backed their appeal to raise 500,000 to afford the life-saving treatment. This is specialised therapy, which is only available in Singapore, to combat his T-cell acute lymphoblastic leukaemia. The young Worcester boy underwent a stem cell transplant last May after a search for a donor which saw thousands across the country to sign-up to a register in a bid to help.

The Worcester News previously reported that Oscar's parents were appealing for blood donations because there's a shortage due to less people donating due to the coronavirus. However, an NHS Blood and Transplant spokesman said blood stock levels are good.

The spokesman said: Our stock levels are good and we dont believe weve seen any effect on appointments. Were asking donors to keep donating as normal and to follow the latest travel and hygiene advice. Donation help us to keep stocks good so we are well prepared for every eventuality. Were regularly reviewing the situation and working closely with the government, Public Health England and the UKs other blood donation services. We're putting in place extra measures and safety is always our number one priority.

See more here:
Oscar Saxelby-Lee gets 'super cells' after having stem cell transplant from dad to fight off cancer - Ledbury Reporter

Study Shows Development of Young Cells Could be New Option in Cancer Care – BioSpace

Washington University School of Medicinein St. Louis released a newstudyabout the effectiveness of immunotherapy based on the age of the cells used. The study, published in the journalDevelopmental Cell,showed that these natural killer cells seem to be more effective when they are young. Natural killer (NK) cells, as they're called, are used in immunotherapy to treat cancer using the body's immune cells or immune cells from a matched donor.

"We are trying to improve the effectiveness of immunotherapy for more patients," said senior author Christopher M. Sturgeon, Ph.D., an assistant professor of medicine.

Typically, NK cells used in investigational immunotherapy are adult and come from the patient or donor bone marrow. While these therapies can work, they don't work for everyone.

In contrast, young NK cells do not use the patient's cell or donor cells. These early NK cells, typically formed in the yolk sac in the early embryo, are instead able to be created with human pluripotent stem cells. They can be manufactured quickly by most academic medical centers, thus eliminating the time it takes to process patient's or donor's cells for typical NK cell therapy.

"This special source of natural killer cells has the potential to fill some of the gaps remaining with adult NK cell therapy. There is early evidence that they are more consistent in their effectiveness, and we would not need to process cells from a donor or the patient. They could be manufactured from existing cell supplies following the strict federal guidelines for good manufacturing practices. The characteristics of these cells let us envision a supply of them ready to pull off the shelf whenever a patient needs them," Sturgeon said.

Instudieswith mice using the lab-developed human pluripotent stem cells to create early NK cells, researchers found positive results. These cells were significantly better at degranulation than adult NK cells. Even cells from umbilical cord blood did not respond as well as the early NK cells. Additionally, early NK cells are a particular type of short-lived immune cell, meaning that even if the cells cause harm, they aren't in the body for very long. However, NK cells, in general, do not attack the body's healthy tissues significantly, unlike many T cell therapies.

"Based on their unique behavior alone, there is one small clinical trial of these cells that is ongoing. Now that we know how to manufacture them and how they work, it opens the door for more trials and for improving upon their function, " Sturgeon said.

More research will need to be put into understanding why these special cells only show up in the early embryo and where they go after.

The origin and why they work so well is still a complete mystery.

"We can only speculate at this point, but it's possible that during early embryonic development, when there is so much rapid cell division, these cells are there as a surveillance mechanism to protect against pediatric cancers or infection," he said.

In addition to the early NK cells, pluripotent stem cells also have the potential to bring about many other different cell types, creating more possibilities.

See the original post here:
Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace

Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer – Yahoo Finance

Press Release

Gosselies, Belgium, 26March 2020, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it is further strengthening its management team with the appointment of Stefanos Theoharis, PhD, as Chief Business Officer (CBO).

Stefanos will be responsible for the companys corporate development activities and executing its business strategy. His immediate priorities will be concentrating on partnering Bone Therapeutics products and in-licensing innovations. He will also further develop the commercial strategies for the product portfolio and cell therapy platform.

At this stage of the development of Bone Therapeutics, it is very important to appoint a proven executive with a high level of business experience to achieve our next set of commercial goals, said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. Stefanos has gathered considerable achievements in business development at both rapidly growing biotech and global biopharma companies, coupled with an extensive expertise in cell therapy drug development and manufacturing. His diverse skill set, which includes licensing, M&A transactions and R&D partnerships, will be invaluable to bolster our business initiatives as we continue to advance our mid- to late stage product pipeline through clinical development with a potential commercialization in sight.

Stefanos will contribute more than 15 years of business development experience in the pharma and biotech industry to Bone Therapeutics, specifically in the cell and gene therapy space. This includes his achievements as Senior Vice-President at Cell Medica, a clinical-stage biotech company, where he expanded the companys allogeneic T-cell immunotherapy platform through strategic partnerships with leading research institutions and targeted acquisitions. Prior to Cell Medica, Stefanos was Chief Business Officer at apceth GmbH, a company developing genetically-engineered mesenchymal stromal (MSC) cell products and also acting as a contract manufacturer in the ATMP space. He led all apceths business development activities, including in- and out-licensing and service contracts negotiations. He also held positions as Head of Business Development at the antisense RNA drug specialist Antisense Pharma (now Isarna), and Director Business Development at Roche, focused on partnering activities in emerging science and technologies. Stefanos also worked at Lazard, the global investment bank, advising to a variety of life sciences firms on M&As and financing transactions. Stefanos achieved an MSc. in Molecular Medicine and a PhD in Pathology and Immunology from Imperial College London.

I really wanted to join a cell therapy company where I was able to make a significant difference to the company, the wider field and patients outcomes. With an innovative allogeneic, off the shelf, cell therapy platform and a potentially best-in-class knee osteoarthritic pain treatment, Bone Therapeutics is uniquely positioned to make a meaningful difference in the lives of patients with severe orthopaedic conditions, said Stefanos Theoharis, PhD, Chief Business Officer of Bone Therapeutics. As both products are entering advanced stage clinical trials, Im delighted to join the company at such a critical time and I look forward to working with its talented leadership and scientific teams to take these promising treatments to market.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering PhaseIII development for the treatment of pain in knee osteoarthritis. Positive PhaseIIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) for the pivotal PhaseIII program has been approved by the Danish relevant authorities allowing the start of the study.

Story continues

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by the Belgian regulatory authority, the Company is ready to start the PhaseIIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: 44 (0)20 8943 4685neil@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See the original post here:
Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer - Yahoo Finance

Uni kit to help with virus tests – Kent Online

With stricter measures now enforced upon the country, staff and students at the University of Kent are doing their bit to try and help with the coronavirus outbreak.

As the bioscience laboratories at the university are now closed, they're lending specialist equipment to hospitals in Kent to help increase the number of coronavirus tests that can be taken, while more than 30 members of staff, academics and PHD students from the biosciences school have also volunteered to help.

KMTV's Kristina Curtis reports on how students and staff at the University of Kent are doing to help tackle the coronavirus outbreak

Prof. Dan Mulvihill, Head of the School of Biosciences at the university said: "Staff, PHD students, researchers and academics have volunteered to give up their time to help in the labs in NHS hospitals.

"We have a variety of people with molecular biology skills, what we're trained to do here, and theyre able to use these skills working alongside NHS workers so we can expand the number of tests that can be done in any one day.

"Weve all been trained in this particular skill set, theres a need for it now and this is the time for us to step up. Were in the privileged position of being able to help and therefore we are."

Dr. Jill Shepherd, a lecturer in stem cell biology at the university, added: "The first thing I think most people in bio-sciences wanted to do is come forward and see what we can do. Its a great opportunity to be able to use the skills that our workforce have, the molecular biology skills that we use to produce great research science every day, to come into the labs to do something to help with something thats happening at the moment.

"Its an interesting time for us, were feeling very privileged to be a part of this and to be able to help with the effort.

"Its one of the positive things that can come out of something like this, people can work together more closely and relationships can be developed further."

The machines that have been lent to the hospitals are Quantitative PCR machines which allow tests to be undertaken to detect if the patients have coronavirus or not. Although hospitals in the county already have access to the machines, having additional ones is hoped to significantly increase the amount of tests that can be carried out each day.

Prof Mulvihill said: "These machines, which we use in our research labs on a daily basis, theyre extremely sensitive so they allow you to detect within samples a trace, or not, of nucleic acid from the virus itself. So we can identify whether or not theyve been infected with a high degree of certainty.

"Our machines will be able to increase the hospitals capacity to fulfil demand in the coming months."All five of the machines are set to be delivered to the hospitals in Kent this week, with the volunteers ready to put their hard-earned skills and research to practice.

The University of Kent is also set to begin working with Imperial College London on a research project to develop antibodies that target the novel coronavirus with the aim of developing a new therapy for COVID-19.

The research project will look to develop a potential antibody therapy, with the aim of progressing the therapy to be ready to for clinical trials. These trials will determine if the developed therapies can treat coronavirus infections including the COVID-19.

For this project, Kent will be working alongside Hong Kong University and the National Institute for Biological Standards and Control, as well as Imperial College.

Positive results from this research could include vital breakthroughs in actions against the virus, putting the NHS in a stronger position and providing hope for the pandemics eventual close.

For the latest coronavirus news and advice, click here.

See the article here:
Uni kit to help with virus tests - Kent Online

Old human cells rejuvenated with stem cell technology – Stanford Medical Center Report

During this process the cells not only shed any memories of their previous identities, but they revert to a younger state. They accomplish this transformation by wiping their DNA clean of the molecular tags that not only differentiate, say, a skin cell from a heart muscle cell, but of other tags that accumulate as a cell ages.

Recently researchers have begun to wonder whether exposing the adult cells to Yamanaka proteins for days rather than weeks could trigger this youthful reversion without inducing full-on pluripotency. In fact, researchers at the Salk Institute for Biological Studies found in 2016 that briefly expressing the four Yamanaka factors in mice with a form of premature aging extended the animals life span by about 20%. But it wasnt clear whether this approach would work in humans.

Sarkar and Sebastiano wondered whether old human cells would respond in a similar fashion, and whether the response would be limited to just a few cell types or generalizable for many tissues. They devised a way to use genetic material called messenger RNA to temporarily express six reprogramming factors the four Yamanaka factors plus two additional proteins in human skin and blood vessel cells. Messenger RNA rapidly degrades in cells, allowing the researchers to tightly control the duration of the signal.

The researchers then compared the gene-expression patterns of treated cells and control cells, both obtained from elderly adults, with those of untreated cells from younger people. They found that cells from elderly people exhibited signs of aging reversal after just four days of exposure to the reprogramming factors. Whereas untreated elderly cells expressed higher levels of genes associated with known aging pathways, treated elderly cells more closely resembled younger cells in their patterns of gene expression.

When the researchers studied the patterns of aging-associated chemical tags called methyl groups, which serve as an indicator of a cells chronological age, they found that the treated cells appeared to be about 1 to 3 years younger on average than untreated cells from elderly people, with peaks of 3 years (in skin cells) and 7 years (in cells that line blood vessels).

Next they compared several hallmarks of aging including how cells sense nutrients, metabolize compounds to create energy and dispose of cellular trash among cells from young people, treated cells from old people and untreated cells from old people.

We saw a dramatic rejuvenation across all hallmarks but one in all the cell types tested, Sebastiano said. But our last and most important experiment was done on muscle stem cells. Although they are naturally endowed with the ability to self-renew, this capacity wanes with age. We wondered, Can we also rejuvenate stem cells and have a long-term effect?

When the researchers transplanted old mouse muscle stem cells that had been treated back into elderly mice, the animals regained the muscle strength of younger mice, they found.

Finally, the researchers isolated cells from the cartilage of people with and without osteoarthritis. They found that the temporary exposure of the osteoarthritic cells to the reprogramming factors reduced the secretion of inflammatory molecules and improved the cells ability to divide and function.

The researchers are now optimizing the panel of reprogramming proteins needed to rejuvenate human cells and are exploring the possibility of treating cells or tissues without removing them from the body.

Although much more work needs to be done, we are hopeful that we may one day have the opportunity to reboot entire tissues, Sebastiano said. But first we want to make sure that this is rigorously tested in the lab and found to be safe.

Other Stanford co-authors are former postdoctoral scholar Marco Quarta, PhD; postdoctoral scholar Shravani Mukherjee, PhD; graduate student Alex Colville; research assistants Patrick Paine, Linda Doan and Christopher Tran; Constance Chu, MD, professor of orthopaedic surgery; Stanley Qi, PhD, assistant professor of bioengineering and of chemical and systems biology; and Nidhi Bhutani, PhD, associate professor of orthopaedic surgery.

Researchers from the Veterans Affairs Palo Alto Health Care System, the University of California-Los Angeles and the Molecular Medicine Research Institute in Sunnyvale, California, also contributed to the study.

The research was supported by the National Institutes of Health (grants R01 AR070865, R01 AR070864, P01 AG036695, R01 AG23806, R01 AG057433 and R01 AG047820), the Glenn Foundation for Medical Research, the American Federation for Aging Research and the Department of Veterans Affairs.

Sarkar, Quarta and Sebastiano are co-founders of the startup Turn Biotechnologies, a company that is applying the technology described in the paper to treat aging-associated conditions. Rando is a member of the scientific advisory board.

Read more from the original source:
Old human cells rejuvenated with stem cell technology - Stanford Medical Center Report

Can cell-based therapy be helpful in tackling coronavirus? – YourStory

Ever since the novel coronavirus, or COVID-19, was first reported in China's Wuhan city, the virus has spread to more than 196 countries and territories around the world with393,284 confirmed cases and17,161 deaths so far. In India, the maximum number of cases has been reported in the state of Maharashtra.The number of coronavirus cases in the country has risen to 519, with 10 deaths.

It is the need of the hour to find a solution for coronavirus.

Clinical trials in China are already testing the efficacy of stem cell therapies for COVID-19. Arecent clinical trialwith seven COVID-19 patients showed that a stem cell product improved patient outcome. According to research published in the peer-reviewed journalAging and Disease,mesenchymal stem cell (MSC) therapy could be effective in treating COVID-19.

Coronaviruses (CoV) belong to a large family of viruses leading to respiratory illnesses, such as common coldto more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute RespiratorySyndrome (SARS-CoV).

Earlier this year, a new strain of coronavirus was discovered, which was not previously identified in humanbeings, also known as the novel coronavirus (nCov). The symptoms of the infection are respiratory issues, fever, cough, shortness of breath, and breathingdifficulties. More severe cases of COVID-19 can cause pneumonia, severe acute respiratory syndrome, and kidneyfailure.

In recent years, scientific research hasshown that MSCs have properties that maymake them very useful to repair damaged tissues in the patients respiratory system and promotefaster healing and recovery.Umbilical cord tissueis particularly rich inthese cells, which is why many parents arechoosing to store them at birth.

MSCs can reduce the overproduction of immune cells caused by a reaction to the virus and reduce excessive levels of inflammatory substances, thus regulating the immune system.

Currently, many vaccines or drugs are being tested to deal with coronavirus. There is widespread fear and phobia among the population. Why not use your own defence system rather than searching for drugs to tackle the virus?

MSCs are multi-potent cells that have been widely used for tissue regeneration and immunomodulation, and can be a potential solution. The infusion of autologous and allogenic MSCs has been proven safe and effective in tissue repair and disease modulation. MSCs have anti-inflammatory, antimicrobial properties; therefore, they have the potential to control inflammatory conditions, possibly viral diseases, and may reduce mortality.

Another interesting therapeutic avenue is immunotherapy. Natural killer (NK) cells, a component of our innate immune system, play an important role in tackling malignancies as well as virally infected cells. These cells serve to contain viral infections while the adaptive immune response is generating antigen-specific cytotoxic T cells that can clear the infection. Thus, NK cell therapy can be safe and effective in the management of COVID-19.

We need to ensure control of person-to-person transmission of the infection. Therefore, stringent isolation/quarantine measures are important until complete recovery of an infected individual.

(Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views of YourStory.)

How has the coronavirus outbreak disrupted your life? Write to us or send us a video with subject line 'Coronavirus disruption' to editorial@yourstory.com

The rest is here:
Can cell-based therapy be helpful in tackling coronavirus? - YourStory

YOUR HEALTH: A rare disease that hardens the skin – WQAD.com

In severe cases, it can also cause deadly hardening of internal organs like the lungs

MADISON, Wis. A year ago, Chuck Beschta couldn't walk more than a few minutes without stopping to rest.

"Just going out and doing normal activities outside raking the lawn mowing the grass shoveling the driveway whatever;snow blowing, those became impossible."

After months of testing he was diagnosed with severe scleroderma, which was hardening his skin but even worse. it was hardening his lungs, making it hard to breathe.

Scleroderma is an autoimmune rheumatic disease where an overproduction of collagen produced in the body tissues.

But in severe cases, it can also cause deadly hardening of internal organs like the lungs, giving some patients little hope of surviving.

Chuck's case was getting more dire.

"He was getting worse despite the best therapy we had to offer," explained Dr. Kevin McKown, a rheumatologist at the University of Wisconsin Hospital in Madison

Dr. McKown recommended a stem cell transplant newly approved for scleroderma to reboot chucks immune system.

"There's a process by which they try to remove the autoreactive immune cells, the cells that are caught in the immune process and then they infuse that back in and hope that the body will basically take up and graft that immune system

Rheumatologists at University of Wisconsin Health tested the treatment since they have already been conducting bone marrow transplants for decades.

Surgeons take out a sample of the patient's bone marrow, isolate the stem cells, and use radiation and chemotherapy to clean out their immune system. The same stem cells are later injected back into the patient's immune system with the hope that new cells will grow and the system is rid of the bad ones.

The process is dangerous when the cells are taken out because the patient's immune system is more vulnerable, making infections more likely to occur.

Chuck saw almost immediate results. His skin was softer and his breathing improved.

He hopes his scleroderma has been cured.

"I think we can be optimistic and so far the people who have been followed out as far as 10 years out don't seem to be getting it back," said Dr. McKown.

After four and a half years, 79% of patients who underwent the treatment were alive without serious complications compared to 50% that were treated with the original drugs.

Without a transplant, less than half the patients, like Chuck, who have diffuse scleroderma and severe lung disease live 10 years past diagnosis. stem cell transplants are commonly used to treat leukemia and lymphoma, cancers that affect the blood and lymphatic system.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens atjim.mertens@wqad.comor Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

See the original post here:
YOUR HEALTH: A rare disease that hardens the skin - WQAD.com

Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL – Cancer Therapy Advisor

Five real-life cases of adult patients with relapsed/refractory CD19-positiveB-cell acute lymphoblastic leukemia (ALL) were recently detailed in an articlein Blood along with the rationalesfor selecting CD19-directed CAR-T therapy or the CD3/CD19 bispecific antibody,blinatumomab, as the first CD19-targeted treatment approach for each patientcase.

While both blinatumomab and CD19-directed CAR-T therapy (ie,tisagenlecleucel in patients 25 years or younger) are approved by the US Foodand Drug Administration (FDA) for the treatment of relapsed/refractory B-cellALL, the mechanisms of action of these therapies are very different: the formerdrug activates T cells by linking them through their CD3 receptor to the CD19surface antigen on B cells, whereas CD19-directed CAR-T therapy uses autologousT cells that have been genetically modified to express the CD19 receptor.

Nevertheless, both treatment approaches are considered tolerable and potentiallycurative in the setting of relapsed/refractory B-cell ALL. Furthermore, it maybe possible to subsequently offer the alternative CD19-targeted treatment ifdisease progression occurs following treatment with either CD19-directed CAR-Ttherapy or blinatumomab. However, some patients will become ineligible for subsequenttreatment with the alternative approach due to loss of B-cell expression ofCD19.

Oncethe decision to use CD19-targeted immunotherapy to treat a patient withadvanced ALL has been made, the physician faces the challenge of selectingbetween blinatumomab and CAR T cells, the study authors noted, adding that itis crucial to weigh all considerations for each individual patient beforeselecting one immunotherapy over another.

Inthe patient cases highlighted in this article, multiple factors were consideredin making individualized treatment decisions.

Forexample, initial treatment with blinatumomab was selected for an older patientwith low-burden disease, given its FDA approval across all age groups, itslower associated risks of severe cytokine release syndrome and neurotoxicitycompared with CAR-T therapy, and its demonstrated efficacy in patients withlow-burden disease. Furthermore, because allogeneic hematopoietic stem celltherapy (allo-HCT) was planned for this patient who had a matched siblingdonor, another factor weighing in favor of blinatumomab was the avoidance of delaysassociated with CAR-T manufacturing.

Factorsassociated with selection of CD19-directed CAR-T therapy as the initialCD19-directed approach included the presence of extramedullary disease in the centralnervous system (CNS), as there is evidence supporting CNS penetration by CAR-Tcells, as well as promising antileukemic activity in patients with extramedullarydisease.

Inaddition, CAR-T therapy was preferred for a patient who experienced diseaseprogression following allo-HCT and was unlikely to receive a second allo-HCT,given evidence for long-lasting remissions even without consolidation allo-HCTfollowing treatment with CAR-T therapy.

Inthis context, the study authors stated that blinatumomab in this setting isbetter used as a bridging therapy rather than a definitivecurative treatment.

The study authors concluded that treatment with blinatumomab and CD19 CAR T cells holds promise in advanced ALL, allowing more patients to attain remission and possible cure with and without additional therapies. Both treatments have unique limitations and advantages, and the treating physician should be discerning when selecting treatment of each case.

Reference

Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.[published online March 12, 2020]. Blood. 2020;135:804-813. doi:10.1182/blood.2019002132

Read this article:
Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL - Cancer Therapy Advisor

Stem Cell Alopecia Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Bandera County Courier

Verified Market Research recently published a research report titled, Stem Cell Alopecia Treatment Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Stem Cell Alopecia Treatment market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=BCC&utm_medium=002

Stem Cell Alopecia Treatment Market Leading Players:

Stem Cell Alopecia Treatment Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Stem Cell Alopecia Treatment market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Stem Cell Alopecia Treatment market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Stem Cell Alopecia Treatment market.

Market Segments: This part of the report discusses about product type and application segments of the Stem Cell Alopecia Treatment market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Stem Cell Alopecia Treatment market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Stem Cell Alopecia Treatment market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Analysis

Read the rest here:
Stem Cell Alopecia Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County Courier

Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio – Yahoo…

The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200323005764/en/

Technavio has published a latest market research report titled Global Autologous Cell Therapy Market 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/autologous-cell-therapy-market-industry-analysis

The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.

The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Autologous Cell Therapy Market Companies:

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.

Story continues

Holostem Terapie Avanzate Srl

Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005764/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Link:
Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Yahoo...